Incannex initiates sixth research program following more positive in vivo results; IHL-675A for rheumatoid arthritis

Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it has received positive results from another in vivo (animal) study that has further assessed the anti-inflammatory capability of its proprietary IHL-675A, which is a drug that combines cannabidiol (‘CBD’) and hydroxychloroquine (‘HCQ’).